Phys Vivas · oncological
Prostate Cancer — Viva Defence
DCE viva defence for Prostate Cancer.
On this page & tools
Target exams
Prostate Cancer Viva
Long Case Viva Defence
Opening statement
"This patient presents with a problem best framed as Prostate Cancer. My priorities are to identify red flags, confirm the mechanism with purposeful investigations, start a sequenced management plan, and integrate multimorbidity and follow-up." [1] [2]
Examiner questions
Q1: "What makes this urgent?" [1]
"I look for threats to airway, perfusion, neurology, metabolism, infection or bleeding, and I escalate those before elective work-up." [1] [2]
Q2: "What is your first investigation package?" [2]
"I order tests that change management now, not a scattergun panel." [1] [2]
Q3: "Walk me through treatment." [1]
"Stabilise, treat the mechanism, prevent complications, and plan monitoring." [1] [2] [3]
Q4: "What is the classic trap?" [2]
"Treating a label without confirming the discriminating mechanism, or delaying escalation." [1] [2]
Short case
Counsel the patient on the plan, risks and warning symptoms in plain language. [1] [2]
References
- [1]Tatarano S, Mitsuke A, Osako Y, Sakaguchi T, et al. NTRK fusion in metastatic castration-resistant prostate cancer treated with entrectinib: a case report J Med Case Rep, 2026.PMID 42469872
- [2]Akinnola OO, Olaniyan AI, Adeboye BA, Akinyosoye AD Impact of immunotherapy as a monotherapy or in combination with conventional therapies on regulatory T-cell (Treg) modulation in prostate cancer: a systematic review BMC Cancer, 2026.PMID 42469702
- [3]Watfa M, Dortche K, Fervaha G, Younis SK, et al. Long-term oncologic outcomes of patients with grade group 1 prostate cancer and pT3a disease on final pathology Prostate Cancer Prostatic Dis, 2026.PMID 42469509
- [4]Melchior F, Koett M, Aigner G, Schroffenegger J, et al. Real-World Use of Prolaris® to Guide Treatment Decisions in Localized Prostate Cancer Eligible for Active Surveillance Urol Int, 2026.PMID 42467602
- [5]Aly M, Joseph A, Amer T The Evidence-Practice Gap in Testosterone Therapy for Prostate Cancer: A Narrative Review Cureus, 2026.PMID 42465160
- [6]Buali HF, Al Shaibani A, Farouqi US, Abushloa T, et al. Prostate Cancer Screening: Current Controversies and Future Directions Cureus, 2026.PMID 42465149
- [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
- [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922